Unichem Laboratories Ltd

₹ 576 0.55%

28 Aug - close price

unichemlabs.com BSE: 506690 NSE: UNICHEMLAB

About

Unichem Laboratories Ltd is involved in pharmaceuticals
in Generics, APIs and Contract Manufacturing (CMO) areas.^[1]

Key Points

Therapeutic Areas
The company manufactures and markets APIs and pharmaceutical formulations as branded & non-branded generics. The company’s products cater to diverse therapeutic areas such as cardiology, gas, diabetology, gastroenterology psychiatry, neurology, antibacterial, anti-infective, and pain management. ^[1]

Website BSE NSE

Market Cap ₹ 4,059 Cr.
Current Price ₹ 576
High / Low ₹ 631 / 395
Stock P/E 1,555
Book Value ₹ 326
Dividend Yield 0.00 %
ROCE -1.06 %
ROE -1.55 %
Face Value ₹ 2.00

Add ratio to table

Edit ratios

Pros

Company has reduced debt.
Company is almost debt free.

Cons

Company has low interest coverage ratio.
The company has delivered a poor sales growth of 8.31% over past five years.
Company has a low return on equity of -3.81% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns

Loading peers table ...

Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024
	201	217	248	277	245	266	252	310	347	334	362	399	390
	230	227	265	264	256	297	294	319	338	341	343	369	350
Operating Profit	-29	-10	-17	12	-11	-31	-42	-9	8	-7	19	31	40
OPM %	-14%	-5%	-7%	5%	-4%	-12%	-17%	-3%	2%	-2%	5%	8%	10%
	13	5	15	9	12	6	15	-104	6	8	78	-119	9
Interest	0	1	0	1	2	3	2	3	2	4	2	2	1
Depreciation	20	20	21	21	23	26	29	28	27	27	26	25	26
Profit before tax	-36	-27	-24	-0	-23	-55	-57	-144	-16	-31	69	-115	21
Tax %	-24%	-19%	0%	-6,289%	0%	38%	0%	0%	0%	0%	0%	0%	0%
	-28	-21	-24	17	-23	-75	-57	-144	-16	-31	69	-115	21
EPS in Rs	-3.95	-3.04	-3.34	2.46	-3.31	-10.72	-8.11	-20.43	-2.23	-4.38	9.84	-16.33	3.05
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	TTM
	1,005	1,044	1,091	1,221	576	666	968	904	1,124	943	1,072	1,442	1,485
	819	863	989	1,078	813	798	1,019	994	1,028	986	1,165	1,391	1,402
Operating Profit	186	181	102	142	-237	-132	-52	-89	95	-43	-93	51	83
OPM %	18%	17%	9%	12%	-41%	-20%	-5%	-10%	8%	-5%	-9%	4%	6%
	14	84	20	19	366	2,737	94	98	47	42	-71	-27	-24
Interest	2	2	2	2	2	3	1	1	1	2	9	10	9
Depreciation	35	43	38	35	39	45	62	71	76	83	106	105	104
Profit before tax	162	220	82	124	87	2,556	-20	-64	66	-87	-279	-92	-55
Tax %	20%	20%	21%	19%	-19%	-0%	-144%	-12%	18%	-36%	7%	0%
	130	177	64	100	104	2,557	9	-56	54	-55	-300	-92	-55
EPS in Rs	14.33	19.52	7.09	11.06	11.43	363.48	1.25	-8.00	7.68	-7.87	-42.57	-13.09	-7.82
Dividend Payout %	31%	41%	28%	18%	26%	1%	320%	-50%	52%	-51%	-9%	0%

Compounded Sales Growth
10 Years:	3%
5 Years:	8%
3 Years:	9%
TTM:	26%

Compounded Profit Growth
10 Years:	%
5 Years:	%
3 Years:	%
TTM:	101%

Stock Price CAGR
10 Years:	10%
5 Years:	27%
3 Years:	27%
1 Year:	38%

Return on Equity
10 Years:	12%
5 Years:	-2%
3 Years:	-4%
Last Year:	-2%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Equity Capital	18	18	18	18	18	14	14	14	14	14	14	14
Reserves	795	888	929	1,009	1,113	2,748	2,718	2,633	2,683	2,658	2,370	2,281
	6	1	0	8	1	0	0	17	1	132	108	70
	314	300	274	306	371	346	298	361	420	318	394	499
Total Liabilities	1,133	1,207	1,222	1,342	1,503	3,108	3,030	3,025	3,119	3,122	2,886	2,864
	426	394	396	381	468	555	789	829	850	963	1,236	1,165
CWIP	129	86	119	233	247	236	90	331	568	494	148	122
Investments	140	120	153	111	89	979	1,042	668	520	390	41	44
	437	607	555	617	698	1,338	1,109	1,197	1,181	1,275	1,462	1,532
Total Assets	1,133	1,207	1,222	1,342	1,503	3,108	3,030	3,025	3,119	3,122	2,886	2,864

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
	180	87	88	117	141	-66	-251	-42	-33	-158	-117	-42
	-127	35	-62	-87	-132	1,648	-323	-36	-73	104	241	60
	-51	-98	-47	-39	-9	-930	-45	-21	-45	96	-62	-48
Net Cash Flow	3	24	-21	-9	-0	653	-619	-98	-150	42	62	-30

Ratios

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Debtor Days	77	74	69	79	188	127	125	130	117	147	161	141
Inventory Days	127	183	159	162	371	216	242	301	326	438	335	264
Days Payable	153	149	122	153	334	220	170	199	159	150	170	132
Cash Conversion Cycle	51	108	106	88	225	123	197	233	284	436	325	274
Working Capital Days	62	102	95	100	233	190	222	221	208	286	267	206
ROCE %	20%	19%	9%	13%	-8%	132%	-0%	-2%	2%	-3%	-6%	-1%

Shareholding Pattern

Numbers in percentages

	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024
	50.93%	50.93%	50.93%	50.93%	50.94%	50.94%	50.94%	50.94%	70.21%	70.22%	70.22%	70.22%
	1.53%	1.45%	1.47%	1.50%	1.71%	1.56%	1.70%	1.62%	0.83%	0.84%	0.90%	0.89%
	9.09%	9.30%	9.59%	9.53%	8.70%	8.21%	8.15%	9.65%	10.00%	10.46%	11.26%	11.57%
	38.44%	38.32%	38.01%	38.04%	38.67%	39.31%	39.21%	37.80%	18.95%	18.47%	17.63%	17.32%
No. of Shareholders	33,892	35,313	33,557	32,666	29,573	30,618	29,418	26,642	21,584	20,877	21,171	20,621

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Jun 2024
	50.08%	50.67%	50.64%	50.74%	50.93%	50.93%	50.94%	70.22%	70.22%
	4.04%	5.34%	2.13%	1.76%	1.50%	1.47%	1.70%	0.90%	0.89%
	12.62%	5.93%	7.28%	9.46%	8.94%	9.59%	8.15%	11.26%	11.57%
	33.26%	38.06%	39.95%	38.04%	38.62%	38.01%	39.21%	17.63%	17.32%
No. of Shareholders	25,539	45,695	39,785	36,355	33,734	33,557	29,418	21,171	20,621

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

All

Annual reports

Credit ratings

Concalls

Jun 2017

Transcript

Notes
PPT
Feb 2017
Transcript PPT
Nov 2016
Transcript PPT
Aug 2016
Transcript PPT
Jun 2016
Transcript PPT
Feb 2016
Transcript PPT